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AbsTrACT
Objective the english Bowel cancer Screening 
Programme (BcSP) recommends 3 yearly colonoscopy 
surveillance for patients at intermediate risk of colorectal 
cancer (crc) postpolypectomy (those with three to 
four small adenomas or one ≥10 mm). We investigated 
whether faecal immunochemical tests (Fits) could reduce 
surveillance burden on patients and endoscopy services.
Design intermediate-risk patients (60–72 years) 
recommended 3 yearly surveillance were recruited within 
the BcSP (January 2012–December 2013). Fits were 
offered at 1, 2 and 3 years postpolypectomy. invitees 
consenting and returning a year 1 Fit were included. 
Participants testing positive (haemoglobin ≥40 µg/g) 
at years one or two were offered colonoscopy early; all 
others were offered colonoscopy at 3 years. Diagnostic 
accuracy for crc and advanced adenomas (aas) was 
estimated considering multiple tests and thresholds. We 
calculated incremental costs per additional aa and crc 
detected by colonoscopy versus Fit surveillance.
results 74% (5938/8009) of invitees were included in 
our study having participated at year 1. Of these, 97% 
returned Fits at years 2 and 3. three-year cumulative 
positivity was 13% at the 40 µg/g haemoglobin threshold 
and 29% at 10 µg/g. 29 participants were diagnosed 
with crc and 446 with aas. three-year programme 
sensitivities for crc and aas were, respectively, 59% 
and 33% at 40 µg/g, and 72% and 57% at 10 µg/g. 
incremental costs per additional aa and crc detected 
by colonoscopy versus Fit (40 µg/g) surveillance were 
£7354 and £180 778, respectively.
Conclusions replacing 3 yearly colonoscopy 
surveillance in intermediate-risk patients with annual 
Fit could reduce colonoscopies by 71%, significantly cut 
costs but could miss 30%–40% of crcs and 40%–70% 
of aas.
Trial registration number iSrctn18040196; results.
InTrODuCTIOn
Most colorectal cancers (CRCs) arise from 
adenomas,1 2 and adenoma removal reduces CRC 
incidence and mortality.3–6 Some patients remain 
at increased risk of CRC postpolypectomy,7 8 and 
national guidelines recommend surveillance by colo-
noscopy.9–12 The UK surveillance guidelines recom-
mend different strategies for patients at low risk, 
significance of this study
What is already known on this subject?
 ► Colonoscopy surveillance is recommended 
for patients who remain at increased risk of 
colorectal cancer (CRC) following polypectomy.
 ► Low-risk, intermediate-risk and high-risk groups 
are defined according to baseline adenoma 
characteristics.
 ► Intermediate-risk patients (with three to four 
adenomas <10 mm or at least one ≥10 mm) 
are recommended 3 yearly colonoscopy 
surveillance.
 ► The burden of postpolypectomy surveillance is 
substantial for both patients and endoscopy 
services.
 ► The faecal immunochemical test (FIT), widely used 
for CRC screening, may be an effective alternative 
to colonoscopy surveillance, but few data are 
available on FIT in surveillance settings.
What are the new findings?
 ► Among intermediate-risk patients, annual FIT was 
well accepted with initial consent and FIT return of 
74% and subsequent FIT return of 97%.
 ► Positivity increased at lower FIT thresholds. 
At the lowest threshold of 10 µg haemoglobin 
per gram (10 µg/g) faeces, 3-year cumulative 
positivity was 29%, compared with 13% at 
40 µg/g.
 ► Sensitivities increased at lower thresholds. 
Three-year programme sensitivities for CRC and 
advanced adenomas (AAs) were, respectively, 
59% and 33% at 40 µg/g and 72% and 57% at 
10 µg/g.
 ► The incremental cost-effectiveness of 
colonoscopy versus FIT surveillance was £7354 
per additional AA detected and £180 778 per 
additional CRC detected.
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intermediate risk and high risk.9 Surveillance is not recommended 
for low-risk patients (with one to two adenomas <10 mm), 
while 3 yearly surveillance is recommended for intermedi-
ate-risk patients (with three to four adenomas <10 mm or at 
least one ≥10 mm). High-risk patients (with five or more 
adenomas <10 mm, or three or more adenomas with at least 
one ≥10 mm) are recommended colonoscopy at 1 year before 
commencing 3 yearly surveillance.
Colonoscopy surveillance is associated with reduced CRC 
incidence8; however, this procedure can have serious complica-
tions and be uncomfortable and anxiety inducing.13 14 Colonos-
copy surveillance places great demand on endoscopy services, 
accounting for 20% of colonoscopies in the UK.15 Further 
increases in endoscopy demand due to widespread implementa-
tion of CRC screening and higher rates of primary care referrals 
for suspected CRC16 give grounds for finding alternative surveil-
lance methods.
The faecal immunochemical test (FIT) may be an alter-
native. Like the guaiac faecal occult blood test (gFOBT), FIT 
detects occult blood in faeces, although it detects globin rather 
than haem, making it more specific for human blood.17 FIT is 
replacing gFOBT in CRC screening programmes because of its 
ease of use, increased uptake, quantitative analysis and greater 
sensitivity for advanced colorectal neoplasia (ACN).18 19 The 
English Bowel Cancer Screening Programme (BCSP) is planning 
to introduce FIT in 2018.20
FIT has been extensively evaluated for screening, with 
sensitivity estimates of a single low-threshold FIT for CRC 
approaching 90%.21 There are few studies on FIT for surveil-
lance, and these reported sensitivities for CRC of 70%–100%, 
although they included patients attending surveillance for 
personal or family histories of CRC.22–27 We therefore devel-
oped the ‘FIT for Follow-Up’ study to investigate the potential 
utility of FIT for postpolypectomy surveillance, looking specifi-
cally at patients deemed at intermediate-risk following screening 
within the BCSP. We focused on intermediate-risk patients as 
they account for most surveillance colonoscopies in the UK.8 28 
Here we report the diagnostic accuracy of annual FIT for CRC 
and advanced adenomas (AAs) over 3 years versus 3 yearly colo-
noscopy, alongside estimates of cost-effectiveness.
MeThODs
study design and participants
Individuals aged 60–72 years were considered eligible if 
deemed at intermediate risk of CRC following colonoscopy 
performed <1 year previously in the BCSP for a positive gFOBT 
and scheduled to undergo 3 yearly colonoscopy surveillance. 
Individuals with >1 baseline colonic examination were excluded 
to prevent overinvestigation from examinations performed early 
due to positive FIT.
Potentially eligible individuals were identified by National 
Health Service (NHS) Digital using the Bowel Cancer Screening 
System (BCSS). Information on these individuals was sent in 
encrypted form by NHS Digital to the BCSP Southern Hub, 
one of five BCSP hubs across England. The hubs send invita-
tions, mail and process faecal occult blood tests and record test 
results for their regional population. Although all five hubs were 
involved in this study, the Southern Hub coordinated all of 
these functions using a bespoke electronic patient management 
system (PMS). Each hub is associated with screening centres; 64 
screening centres were involved in this study.
From January 2012 to December 2013, the Southern Hub 
sent invitations to consecutive individuals meeting the eligibility 
criteria, together with a participant information sheet, consent 
form and FIT kit. The kit contained a FIT device (OC-AUTO 
Sampling Bottle 3, Eiken Chemical Co Ltd, Japan), instructions, 
a plastic zip-lock bag and a prepaid envelope to return the kit to 
the Southern Hub.
Individuals who consented and returned an analysable FIT 
were included. Kits received >10 days after sample collection 
were not accepted. Samples were refrigerated on receipt and 
analysed within 1 week using the OC-Sensor DIANA analyser 
and new formulation sample buffer29 (Eiken Chemical Co Ltd, 
supplied by MAST Group Ltd, UK), according to manufacturer 
instructions. Results were entered on to the PMS. Repeat kits 
were dispatched to individuals who had lost theirs or had inade-
quate or spoilt samples.
We initially used a positivity threshold of 20 µg haemoglobin 
per gram (µg/g) faeces. At this threshold, the positivity rate of 
the first 65 kits was 9.2%, higher than expected from the liter-
ature.30 31 We were concerned that if this rate was sustained, 
too many participants would be offered early colonic exam-
inations and no further FITs, putting pressure on endoscopy 
services and affecting our ability to model FIT performance 
at different thresholds. The threshold was therefore raised to 
40 µg/g. Of the six kits classed as positive using the 20 µg/g 
threshold, three had readings below 40 µg/g. These were not 
retrospectively reclassified as negative following the threshold 
change.
Participants were offered FITs at 1, 2 and 3 years postpolyp-
ectomy. Participants testing positive at years 1 or 2 were offered 
early colonic examination and no further FITs. Participants not 
attending the early examination were invited to the 3-year exam-
ination, as per UK guidelines.9 Participants testing negative at 
years 1 or 2 were offered further FITs, as were those who did 
not complete their year 2 FIT. All participants offered a year 3 
FIT were invited to the routine 3-year examination. Findings at 
colonic examination (early or 3 year) were the reference stan-
dard against which we measured the diagnostic accuracy of FIT.
The default colonic examination was colonoscopy performed 
by accredited endoscopists, the ‘gold-standard’ for detection of 
colorectal lesions.32 CT colonography was an alternative for 
participants unfit for colonoscopy. Endoscopy findings were not 
known by those interpreting FIT results; however, endoscopists 
may have been aware when examinations were for positive FIT 
results.
Data collection and management
FIT results were reported as positive or negative to participants 
and their general practitioners. For participants testing posi-
tive at years 1 or 2, affiliated screening centres were informed 
of their participation in the study, positive FIT result and that 
they should be offered an early colonic examination. Early 
significance of this study
how might it impact on clinical practice in the foreseeable 
future?
 ► Replacing 3 yearly colonoscopy surveillance in intermediate-
risk patients with annual FIT could reduce numbers of 
colonoscopies by ≥70% and produce significant cost savings.
 ► Annual FIT could, however, miss 30%–40% of CRCs and 
40%–70% of AAs, depending on the threshold used.
 ► Further economic analyses and longer term studies are 
warranted to define a clear role for FIT in surveillance.
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examinations were organised by Specialist Screening Practi-
tioners and administrators at the screening centres.
Colonic examination and pathology reports from early and 
3-year examinations were obtained from screening centres. 
Patient, procedural and polyp data from these reports were 
entered on to the PMS using standard operating procedures. 
For some participants (n=28), we could not obtain all reports 
from screening centres, and the BCSS was used as a supplemen-
tary data source. Some participants received examinations at 
hospitals outside the BCSP. When made aware of this, usually 
by participants contacting the BCSP, we attempted to retrieve 
the reports; reports for 42 participants were retrieved in this 
way.
Colonic examinations occurring between consent date and 
18 months after scheduled 3-year examination were included. 
Participants with examinations known to be incomplete or 
have poor visualisation (n=32) were not included as having 
examinations performed, as we could not determine accurately 
whether colorectal lesions were present. Participants may have 
undergone a combination of colonic examinations or surgery; 
all procedures were considered when defining outcomes of CRC 
and AAs. Cancer diagnoses to the end of 2014 were obtained 
from the English cancer registry. Participants with no record of 
a colonic examination occurring during the study but found to 
have CRC in registry data (n=2) were included as having exam-
inations with CRC detected.
Polyp size was defined by the largest diameter reported 
on colonic examination, pathology or surgical reports. 
Adenomas ≥10 mm, with high-grade dysplasia, villous or tubu-
lovillous histology were defined as AAs. We defined CRC sites by 
the International Classification of Diseases 10th revision, using 
codes C18–C20. We coded CRC morphologies using Interna-
tional Classification of Diseases for Oncology 2nd edition codes, 
including 8070/3, 8140/3, 8210/3, 8240/3, 8244/3, 8263/3, 
8480/3 and 8481/3. We included all histological subtypes of 
CRC that arose in our dataset in our main analysis as surveil-
lance programmes would ideally detect all cancers in the lower 
GI tract.
statistical analysis
Our sample size calculation was based on an estimated relative 
sensitivity for ACN of three annual FITs versus 3 yearly colo-
noscopy. Assuming an ACN prevalence of 2.5%, relative FIT 
sensitivity of 75% and 40% compliance with all tests, 72 cases, 
2881 adherent participants and 8000 invitees were required to 
provide sensitivity estimates with 95% CIs within ±10% and 
margin of error of ±10%.
We calculated rates of FIT return and positivity and diagnostic 
yields of CRC and AAs in participants who underwent colonic 
examination following positive FIT. We analysed the sensi-
tivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) of FIT for CRC and AAs at the 40 µg/g 
threshold. For the analyses of diagnostic accuracy for AAs, we 
excluded participants with CRC as we expected their inclusion 
would lead to biased estimates because FIT is more sensitive for 
CRC than AAs.33
We estimated diagnostic accuracy at lower thresholds (10 µg/g, 
20 µg/g and 30 µg/g) and with multiple tests, assuming that any 
ACN detected was present from year 1, remaining unchanged 
over successive years in the absence of colonic examination. 
Considering thresholds below 40 µg/g, we assumed that partic-
ipants with faecal haemoglobin levels above the particular 
threshold underwent hypothetical early examinations, which 
detected what was actually found later on. Results from subse-
quent FITs were excluded from these analyses.
For analyses with multiple tests, we conducted cumulative test 
and programme analyses. For cumulative test analyses, partici-
pants were included if they completed the designated number of 
FITs (two for two-test analyses; three for three-test analyses) or 
tested positive with a previous FIT. All study participants were 
included in programme analyses; in two-test analyses, partici-
pants were ‘positive’ if they tested positive with either of their 
first two FITs, while in three-test analyses, participants were 
‘positive’ if they tested positive with any FIT.
We conducted subgroup analyses by sex and age (≤65 years 
and >65 years) at invitation date. In sensitivity analyses, we 
examined effects on diagnostic accuracy estimates of excluding 
non-adenocarcinomas (squamous cell carcinomas and neuroen-
docrine tumours); these are rare cancers that account for <5% 
of CRCs.34 35 Further sensitivity analyses involved excluding 
participants with colonic examinations of unknown quality and 
those with IBD.
We assessed 3-year surveillance costs of annual FIT with colo-
noscopy in positive cases versus 3 yearly colonoscopy, calculating 
total costs and mean costs per participant. Cost-effectiveness 
was presented as incremental costs per additional AA and CRC 
detected by colonoscopy versus FIT surveillance. We estimated 
the budget impact of replacing colonoscopy with FIT surveil-
lance nationally over a screening cycle (supplementary material: 
Economic analysis of faecal immunochemical test versus colo-
noscopy surveillance).
Analyses were performed in Stata/IC V.13. The protocol is 
online.36
resulTs
There were 9851 potentially eligible individuals. Of these, we 
excluded 186 with multiple baseline examinations and 109 due 
to informed dissent, clinical reasons, death or emigration. An 
additional 1547 individuals were not invited as the sample size 
of 8000 had been met. In total, 8009 individuals were invited 
(figure 1). The proportions of invitees aged ≤65 years and >65 
years were, respectively, 49.3% and 50.7%; 34.7% were women 
(table 1).
Of those invited, 2060 were not recruited: 2055 did not 
consent and five consented but did not return an analysable 
FIT. A further 11 were excluded due to withdrawal of consent, 
baseline CRC, baseline high-risk adenomas, prolonged baseline 
episode or symptomatic exam before year 1 (figure 1). There-
fore, 5938 of 8009 (74.1%) invitees were recruited, having 
consented and returned an analysable FIT (table 1). Return of 
FIT was 97% at years 2 and 3 (table 2). Participation was similar 
among men and women and across age groups (online supple-
mentary tables 1 and 2).
FIT positivity decreased from 5.8% to 4.1% over years 1–3. 
Cumulative positivity over 3 years was 13.2% (table 2) and 
greater in men than women (14.7% vs 10.4%) and in partici-
pants aged >65 years than those ≤65 years (14.3% vs 12.1%) 
(online supplementary tables 1 and 2).
Colonic examinations were performed at some time during 
the study in 5225 of 5938 (88.0%) participants, yielding CRC 
in 29 (0.6%) and AAs in 446 (8.5%) (table 2). There were six 
participants with CRC and AAs. Of the 29 CRCs, 15 were prox-
imal and 14 distal to the splenic flexure, and 26 were adenocar-
cinomas. Of the 26 CRCs with stage information, 10 were stage 
III or IV (online supplementary table 3).
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Figure 1 Participant flow diagram from invitation through to year 3 colonic examination. *Two hundred and ninety-five potentially eligible 
individuals were not invited as they were excluded after the eligibility assessment (186 in order to prevent over-investigation as they had already 
undergone more than one colonoscopy and 109 due to informed dissent, clinical reasons, death or emigration) and a further 1547 individuals were 
not invited as the sample size of 8000 had already been met.†Two thousand and fifty-five individuals were not recruited due to lack of consent; one 
consented but did not return their FIT; and four consented but returned a FIT that could not be analysed. AAs, advanced adenomas; CRC, colorectal 
cancer; FIT, faecal immunochemical test; gFOBT, guaiac faecal occult blood test. 
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Over 3 years, 725 (12.2%) participants underwent colonic 
examination following positive FIT, finding CRC in 17 (2.3%) 
and AAs in 151 (20.8%) (table 2). FIT therefore identified 58.6% 
of participants with CRC (17/29) and 33.9% of participants with 
AAs (151/446) over 3 years at a threshold of 40 µg/g. Diagnostic 
yields at years 1, 2 and 3 were, respectively, 2.5%, 3.2% and 
1.1% for CRC, and 24.4%, 17.1% and 19.0% for AAs (table 2).
FIT positivity was higher at lower thresholds. In programme 
analysis, 3-year positivity was 13.2% at 40 µg/g, and 28.8% at 
10 µg/g (table 3). Sensitivities for CRC increased while specifici-
ties decreased at lower thresholds and with multiple tests. Sensi-
tivities and specificities of the first FIT were, respectively, 27.6% 
and 94.1% at 40 µg/g, and 51.7% and 86.2% at 10 µg/g (table 4). 
Over 3 years, programme sensitivities were 58.6% at 40 µg/g and 
72.4% at 10 µg/g, and programme specificities were 86.4% at 
40 µg/g and 71.1% at 10 µg/g. Similar patterns were observed in 
cumulative test analyses (table 4). Diagnostic accuracy estimates 
at 30 µg/g and 20 µg/g are shown in online supplementary table 
4.
At lower thresholds, greater proportions of FIT-detected 
CRCs were found at year 1 (71.4% at 10 µg/g versus 47.1% at 
40 µg/g) (data not shown). PPVs for CRC were smaller at lower 
thresholds and with multiple tests. In programme analysis after 
3 years, PPVs were 2.4% at 40 µg/g and 1.4% at 10 µg/g. NPVs 
fell between 99.6% and 99.9% for all thresholds and numbers 
of tests (table 4).
Subgroup analyses by sex and age were underpowered; 
however, sensitivities were generally higher in older (>65 years) 
participants, while specificities were generally higher in younger 
(≤65 years) participants and women (online supplementary 
tables 5 and 6).
FIT was less sensitive but more specific for AAs than CRC. 
Sensitivities for AAs increased and specificities decreased at 
lower thresholds and with multiple tests. Three-year programme 
sensitivities for AAs were 33.4% at 40 µg/g and 56.6% at 10 µg/g, 
and programme specificities were 88.3% at 40 µg/g and 73.7% 
at 10 µg/g (table 5). PPVs were higher and NPVs lower for AAs 
than for CRC (table 5).
Although lacking in power, subgroup analyses revealed 
that sensitivities for AAs were slightly higher and specific-
ities lower in men and older (>65 years) participants (online 
supplementary tables 7 and 8). Excluding participants with 
Table 1 Baseline characteristics of invited individuals by participation
sex
Age at invitation 
date (years)
Invited Participants* non-participants*
P value†n (%)‡ n (%) n (%)
All All ages 8009 (100.0) 5938 (74.1) 2071 (25.9)
≤65 3950 (49.3) 2877 (72.8) 1073 (27.2) 0.008
>65 4059 (50.7) 3061 (75.4) 998 (24.6)
Men All ages 5228 (65.3) 3892 (74.4) 1336 (25.6)
≤65 2634 (32.9) 1901 (72.2) 733 (27.8) <0.001
>65 2594 (32.4) 1991 (76.8) 603 (23.2)
Women All ages 2781 (34.7) 2046 (73.6) 735 (26.4)
≤65 1316 (16.4) 976 (74.2) 340 (25.8) 0.501
>65 1465 (18.3) 1070 (73.0) 395 (27.0)
*Participants were individuals who gave consent, returned an analysable FIT at year 1 and did not subsequently withdraw from the study.
†P values are for the comparison of age at invitation date for participants and non-participants, overall and by sex.
‡Percentage of the total invited cohort (8009).
Table 2 Uptake, positivity rate and diagnostic yield of the faecal immunochemical test (FIT) at years 1, 2 and 3 and over all 3 years
uptake Positivity rate Colonic exam performed Diagnostic yield*
Invited Completed FIT test† Tested positive‡ Any exam§ Colonoscopy¶ Colorectal cancer
Advanced 
adenomas**
Year n n (%) n (%) n (%) n (%) n (%) n (%)
  1 8009 5938 (74.1) 346†† (5.8) 320 (92.5) 317 (99.1) 8 (2.5) 78 (24.4)
  2 5479 5329 (97.3) 236 (4.4) 216 (91.5) 212 (98.1) 7 (3.2) 37 (17.1)
  3 5179 5022 (97.0) 204 (4.1) 189 (92.6) 184 (97.4) 2 (1.1) 36 (19.0)
  Cumulative 8009 5938 (74.1) 786‡‡ (13.2) 725 (92.2) 713 (98.3) 17 (2.3) 151 (20.8)
routine 
year 3 colonic exam 4500 4420 (98.2) 12 (0.3) 295 (6.6)
entire study 
findings 5225 5133 (98.2) 29 (0.6) 446 (8.5)
*Diagnostic yield in participants who underwent colonic examination.
†Participants who gave consent, returned an analysable FIT at year 1 and did not subsequently withdraw from the study.
‡Percentages calculated using the number of participants who completed FIT as the denominator. In the pilot study, a threshold of 20 µg haemoglobin (Hb)/g faeces was used to 
denote test positivity. The positivity threshold used in the rest of the study was 40 µg Hb/g faeces.
§Participants who underwent colonoscopy or CT colonography. Percentages calculated using the number of FIT positive participants as the denominator.
¶Participants who had a colonoscopy. Percentages calculated using the number of participants who underwent colonic examination as the denominator.
**Advanced adenomas were defined as adenomas ≥10 mm, with villous or tubulovillous histology, or high-grade dysplasia.
††Three participants tested positive at year 1 during the pilot study based on a threshold of 20 µg Hb/g. They are included as FIT positive in this table even though their faecal 
haemoglobin levels were lower than the 40 µg Hb/g threshold used in the rest of the study.
‡‡Participants who were FIT positive with any FIT, regardless of whether they had completed all FITs that they were offered.
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non-adenocarcinomas (squamous cell carcinoma: n=1; neuro-
endocrine tumours: n=2) saw 3-year programme sensitivities for 
CRC increase from 72.4% to 80.8% at 10 µg/g (data not shown). 
Excluding participants with colonic examinations of unknown 
quality (n=587) or with confirmed IBD (n=19) had negligible 
effects on diagnostic accuracy estimates, although excluding 
participants with confirmed or possible IBD (n=68) saw the 
3-year programme sensitivity for CRC increase to 75.0% at 
10 µg/g (data not shown).
The mean incremental cost per participant for 3 yearly colo-
noscopy surveillance versus 3 years of annual FIT (40 µg/g) was 
£365, and the total cost difference was £2 169 341. Incremental 
costs per additional AA and CRC detected by colonoscopy 
surveillance were £7354 and £180 778, respectively. Replacing 
colonoscopy with FIT surveillance nationally over a screening 
cycle would have a significant impact on budget savings: the 
total saving was estimated to be £4.7 million (online supplemen-
tary figure 1 and supplementary tables 9–12).
DIsCussIOn
In this study, we evaluated the potential of annual FIT for post-
polypectomy surveillance of intermediate-risk patients instead of 
3 yearly colonoscopy. Annual FIT was well accepted with initial 
consent and FIT return of 74% and subsequent FIT return of 
97% and less costly than colonoscopy surveillance. Sensitivities 
increased at lower FIT positivity thresholds; at a threshold of 
10 µg/g, 3-year programme sensitivities were 72% for CRC and 
57% for AAs.
Increased FIT sensitivity was accompanied by increased posi-
tivity and reduced specificity. Compared with one FIT at 40 µg/g, 
3 years of low-threshold (10 µg/g) FIT was associated with five 
times as many positive and false positive results. Nevertheless, 
even with the latter regimen, cumulative positivity was only 29%. 
Substituting 3 yearly colonoscopy in intermediate-risk patients 
with low-threshold annual FIT could therefore reduce numbers 
of colonoscopies by 71%. However, this strategy would increase 
Table 3 Positivity rate of the faecal immunochemical test (FIT) at different thresholds in participants who completed one, two, or three tests
FIT threshold
(µg/g) Test
All
Completed test* Tested positive
n n (%)
40 First 5938 343† (5.8)
Second‡ 5459 245 (4.5)
Third§ 4892 195 (4.0)
Over two tests CTA¶ 5802 588 (10.1)
PA** 5938 588 (9.9)
Over three tests CTA†† 5480 783 (14.3)
PA‡‡ 5938 783 (13.2)
30 First 5938 415 (7.0)
Second‡ 5393 293 (5.4)
Third§ 4785 238 (5.0)
Over two tests CTA¶ 5808 708 (12.2)
PA** 5938 708 (11.9)
Over three tests CTA†† 5493 946 (17.2)
PA‡‡ 5938 946 (15.9)
20 First 5938 545 (9.2)
Second‡ 5274 357 (6.8)
Third§ 4616 291 (6.3)
Over two tests CTA¶ 5819 902 (15.5)
PA** 5938 902 (15.2)
Over three tests CTA†† 5518 1193 (21.6)
PA‡‡ 5938 1193 (20.1)
10 First 5938 841 (14.2)
Second‡ 4986 487 (9.8)
Third§ 4225 384 (9.1)
Over two tests CTA¶ 5857 1328 (22.8)
PA** 5938 1328 (22.4)
Over three tests CTA†† 5553 1712 (30.8)
PA‡‡ 5938 1712 (28.8)
*Participants who tested positive at a given threshold at year 1 or 2 were excluded from subsequent analyses.
†Three participants tested positive at year 1 during the pilot study based on faecal haemoglobin levels higher than 20 µg haemoglobin (Hb)/g but lower than the 40 µg Hb/g 
threshold used in the rest of the study. In this table, they only appear as FIT positive if their faecal haemoglobin levels met the stated thresholds.
‡Includes participants who completed their second FIT, either at year 2 or 3.
§Includes participants who completed their third FIT.
 ¶Includes participants who completed at least two FITs or who tested positive at year 1. Participants were classed as positive if they tested positive with either of their first two 
FITs.
**Includes participants who completed at least one FIT. Participants were classed as positive if they tested positive with either of their first two FITs.
††Includes participants who completed all three FITs or who tested positive with any FIT. Participants were classed as positive if they tested positive with any FIT.
‡‡Includes participants who completed at least one FIT. Participants were classed as positive if they tested positive with any FIT.
CTA, cumulative test analysis; PA, programme analysis.
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the risk of missing ACN; in our data, 28% of CRCs would have 
been missed. Although this percentage has limited precision 
owing to few CRC outcomes (n=29), it may cause concern as 
diagnostic delay can result in disease progression. Additional 
concern may arise from the fact that 30% of FIT-detected CRCs 
were not found until years 2 and 3, even with the low-threshold. 
If in practice FIT return following a negative result is depressed 
by false reassurance, the proportion of cancers missed by FIT 
could be even higher.
This discussion requires consideration of what is an ‘accept-
able’ proportion of missed cancers, accounting for the possibility 
that missed cancers could be detected at treatable stages with 
continued FIT surveillance. This comes with the caveat that FIT 
return may fall following repeat negative testing. Delayed detec-
tion of AAs is less serious given the slower rate of transformation 
from adenoma to cancer,1 37 and a 3-year programme sensitivity 
of 57% may be considered acceptable.
It is interesting to consider these results in light of the findings 
of our ‘Intermediate Adenoma’ study.8 38 Analysing long-term 
CRC incidence in intermediate-risk patients postpolypectomy, 
we identified two risk subgroups. In the higher risk subgroup, 
comprising patients with suboptimal quality colonoscopies, 
adenomas ≥20 mm, high-grade adenomas or proximal polyps at 
baseline, colonoscopy surveillance was associated with a halving 
in incidence. In lower risk patients without these features, the 
value of surveillance was unclear. Therefore, while higher risk 
patients significantly benefit from 3 yearly colonoscopy, annual 
FIT may suffice for lower risk patients. FIT may also be useful in 
the surveillance of high-risk patients; for example, as a substitute 
for the 1-year colonoscopy. Future studies should investigate FIT 
performance in different risk subgroups.
Further research is needed to understand the influence of sex 
and age on FIT performance. Consistent with the literature, 
higher positivity was observed in men and older participants, 
reflecting the increased prevalence of ACN.19 39 40 Sensitivities 
were generally higher and specificities lower in men and older 
participants, although subgroup analyses lacked power. Other 
studies have reported variability in diagnostic accuracy of FIT by 
sex and age, leading to recommendations for individualisation 
of positivity thresholds.19 39 40 PPVs are particularly important 
as they indicate the probability of a colonoscopy being unnec-
essary following positive FIT. Here we did not detect a consis-
tent pattern due to insufficient power, but a study of the Basque 
Country CRC Screening Programme found PPVs of FIT for 
ACN to be significantly higher in men than women at thresh-
olds between 20 µg/g and 60 µg/g.39 Well-powered studies should 
investigate whether this is also the case in individuals undergoing 
surveillance.
FIT sensitivity varies according to lesion type and location. 
Here we reported higher sensitivities when the three non-ade-
nocarcinomas were excluded; these were not detected by FIT, 
even at 10 µg/g. Poor sensitivity has also been reported for 
proximal and serrated lesions.41 Sensitivity may be improved by 
combining FIT with other faecal biomarker tests.42 A multitarget 
molecular stool test has shown greater sensitivity than FIT for 
ACN and for proximal and large serrated lesions, although has 
lower specificity.41 43 An evaluation of FIT and molecular stool 
testing as alternatives to colonoscopy surveillance is underway,44 
although further research should examine how these perform in 
combination.
Intermediate-risk patients are currently recommended to 
undergo surveillance until they have two consecutive negative 
colonoscopies.45 Stopping rules for FIT-based surveillance would 
have to consider the susceptibility of some patients to repeatedly 
test false positive; something we observed in our analysis of 
BCSP participants who underwent gFOBT screening.46
To our knowledge, this study is the largest to have evalu-
ated FIT for surveillance and the only to have evaluated FIT 
specifically in patients undergoing postpolypectomy surveil-
lance. Previous studies included patients attending surveillance 
for personal or family histories of CRC.22–27 In four of these, 
sensitivities were calculated for a single FIT performed prior to 
surveillance colonoscopy.23–26 One study of 808 patients reported 
sensitivities of 70% for CRC and 44% for AAs for Hemeselect, 
a qualitative FIT that was deemed positive when the concen-
tration of faecal haemoglobin exceeded 200–300 µg/g.23 The 
OC-Sensor (10 µg/g) achieved sensitivities for CRC and AAs, 
respectively, of 80% and 28% in a study of 1041 patients,24 and 
100% and 44% in a study of 1000.25 A fourth study stratified 
sensitivity estimates by indication for surveillance, showing that 
in 348 patients undergoing surveillance for colorectal neoplasia, 
sensitivities of OC-Sensor (15 µg/g) were 100% for CRC and 
68% for AAs.26
These studies reported higher sensitivities than we estimated 
for one FIT at 10 µg/g (52% for CRC; 33% for AAs), although 
small numbers of CRCs meant estimates were imprecise. Differ-
ences in patient mix, number of tests, scheduling of FIT relative 
to colonoscopy and the high quality of colonoscopy in England 
may have contributed to the discrepancy. There is one other 
study that evaluated FIT for surveillance with repeated testing27; 
among 1071 patients who completed at least one qualitative 
FIT between surveillance colonoscopies, sensitivities were 86% 
for CRC and 63% for AAs. In our study, sensitivities in patients 
completing at least one FIT was lower at 72% and 57% for CRC 
and AAs, respectively, over 3 years at 10 µg/g.
Strengths of our study include the relatively large sample of 
clearly defined patients undergoing postpolypectomy surveil-
lance and evaluation of FIT at various thresholds and with 
multiple tests. We tested the robustness of our results in sensi-
tivity analyses, observing little change when participants with 
unknown quality examinations and IBD were excluded. The 
high FIT return rates are a further strength, although it is likely 
that our inclusion criteria inflated rates at years 2 and 3 because 
only individuals consenting and returning an analysable year 1 
FIT were offered further FITs, limiting the generalisability of 
our findings. This may have also biased our diagnostic accuracy 
estimates because individuals who provided consent but not an 
analysable FIT may have participated at subsequent years.
Limitations of this study include that it examined FIT perfor-
mance only in relation to the first surveillance colonoscopy. We 
do not know the effect of continuing with FIT beyond 3 years. 
Furthermore, we assumed that colonic examinations detected all 
ACN; given that 98% of participants who underwent examina-
tion had colonoscopy, the ‘gold-standard’ investigation,32 this 
assumption is reasonable. That said, colonoscopy is not perfectly 
sensitive and occasionally misses adenomas and CRCs.47 48 A 
small percentage of participants received CT colonography only, 
which shows comparable sensitivity to colonoscopy for CRC 
and large polyps.13
Another limitation is that endoscopists may have been aware 
when examinations were for positive FIT results, which may have 
influenced the thoroughness of examination, potentially leading 
to inflated sensitivity estimates of FIT-positive colonoscopies. 
Additionally, we assumed that the population of ACN was static. 
Adenoma progression rates are thought to be low1 37 49; however, 
if neoplastic progression did occur, our reported sensitivities may 
be biased. The bias may be in either direction depending on the 
FIT threshold being considered, leading to both underestimation 
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and overestimation of sensitivity. Biases may have resulted from 
missing information, as we did not know why some individuals 
had multiple baseline examinations and were therefore excluded 
or why some did not attend any colonic examination.
Interpretation of our results should take into account the 
specific nature of the study population, namely that it was drawn 
from BCSP participants assigned as intermediate-risk at colonos-
copy performed following positive gFOBT. Generalisability is 
not limited by the use of a single FIT brand, as different brands 
can achieve almost equal sensitivity when thresholds are set to 
yield defined positivity rates.33
COnClusIOn
Our results suggest that FIT could perform a role in postpolypec-
tomy surveillance of intermediate-risk patients. If low-threshold 
annual FIT was implemented instead of 3 yearly colonoscopy, 
numbers of colonoscopies could be reduced by more than 70% 
with significant cost savings. However, this would come at the 
cost of missed ACN; depending on the threshold, annual FIT 
could miss 30%–40% of CRCs and 40%–70% of AAs. Further 
research is warranted before decisions are made about whether 
it is reasonable to adopt FIT for surveillance. Future studies 
should investigate FIT performance in longer term surveillance 
and within subgroups of intermediate-risk patients. Further 
economic analyses should examine the cost implications of 
CRCs and AAs missed by FIT and the impact on quality-adjusted 
life years.
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